RIGA - Latvian technologies companies Latvijas Mobilais Telefons (LMT) and MikroTik have developed a large-capacity data network that would help medics and scientists in their research of cancer, Covid-19 and other diseases, LMT spokeswoman Elina Lidere told LETA.
She said that when using the currently available data network, scientists had to send large amounts of data for genome research for several days or transport them by road in external hard drives. This has slowed down the research process. Now, free-of-charge LMT and MikroTik data network is available, allowing to send large amounts of data in a couple of minutes.
A press conference on the new data network will be held on July 29 on Zoom platform.
The press conference will be attended by Health Minister Ilze Vinkele (For Development), LMT president Juris Binde, MikroTik director John Tully, Latvian Biomedical Research and Study center director Janis Klovins, Latvia MGI Tech head Andis Slaitas, Children's Clinical University Hospital board chairman Valts Abols.
As reported, LMT last year generated EUR 186.099 million in turnover, up 6.4 percent from a year ago, while the company's profit increased 9.3 percent to EUR 30.566 million. LMT was established in January 1992 and its share capital is EUR 817,000. Sonera Holding and Telia Company each own 24.5 percent of LMT shares, 23 percent of the shares belong to TET and Latvian State Radio and Television Center each, while Latvian Public Assets Manager Possessor owns 5 percent of LMT shares.
MikroTik was established in 1996, and has a share capital of EUR 2,840. In 2018, the company posted EUR 258.711 million in turnover and EUR 73.349 million in profit. The company belongs in equal parts to Latvian national Arnis Riekstins and US citizen Martin John Tully.